KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Cash: 2009-2025

Historic Change in Cash for Teva Pharmaceutical Industries (TEVA) over the last 12 years, with Sep 2025 value amounting to $42.0 million.

  • Teva Pharmaceutical Industries' Change in Cash fell 96.04% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 204.30%. This contributed to the annual value of $74.0 million for FY2024, which is 81.17% down from last year.
  • According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' Change in Cash is $42.0 million, which was down 90.95% from $464.0 million recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Change in Cash ranged from a high of $1.1 billion in Q3 2024 and a low of -$1.6 billion during Q1 2025.
  • For the 3-year period, Teva Pharmaceutical Industries' Change in Cash averaged around -$57.3 million, with its median value being -$18.0 million (2024).
  • Within the past 5 years, the most significant YoY rise in Teva Pharmaceutical Industries' Change in Cash was 410.69% (2023), while the steepest drop was 1,365.38% (2023).
  • Teva Pharmaceutical Industries' Change in Cash (MRQ) stood at $153.0 million in 2021, then soared by 276.47% to $576.0 million in 2022, then skyrocketed by 69.62% to $977.0 million in 2023, then crashed by 101.84% to -$18.0 million in 2024, then skyrocketed by 333.33% to $42.0 million in 2025.
  • Its Change in Cash stands at $42.0 million for Q3 2025, versus $464.0 million for Q2 2025 and -$1.6 billion for Q1 2025.